NuCana to Participate in the 7th Annual Truist Securities Life Sciences Summit
April 28, 2021 08:00 ET | NuCana plc
EDINBURGH, United Kingdom, April 28, 2021 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA) announced today that Hugh Griffith, Chief Executive Officer, and Don Munoz, Chief Financial Officer, will host...
NuCana Announces Five Poster Presentations at the American Association for Cancer Research (AACR) Annual Meeting 2021
April 10, 2021 08:30 ET | NuCana plc
NUC-3373 Shows Encouraging Efficacy Signals and a Favorable Safety Profile in Patients with Advanced Colorectal Cancer NUC-3373 Promotes Natural Killer Cell Activation by Colorectal Cancer...
NuCana Reports Fourth Quarter and Year-End 2020 Financial Results and Provides Business Update
March 04, 2021 16:01 ET | NuCana plc
Presented Encouraging Clinical Data for NUC-3373 and NUC-7738 Continued to Enroll Global Phase III Biliary Tract Cancer Study (NuTide:121) of Acelarin with Potential for Accelerated Approval Filing ...
NuCana to Participate in Three Upcoming Investor Conferences
February 25, 2021 08:00 ET | NuCana plc
EDINBURGH, United Kingdom, Feb. 25, 2021 (GLOBE NEWSWIRE) -- NuCana plc (Nasdaq: NCNA) announced today that Hugh Griffith, Chief Executive Officer, and Don Munoz, Chief Financial Officer, will...
NuCana Presents Encouraging Data at ASCO GI for NUC-3373 in Heavily Pre-Treated Patients with Metastatic Colorectal Cancer
January 15, 2021 08:01 ET | NuCana plc
Promising Efficacy Signals Including a 62% Disease Control Rate and a Partial Response in Patients who had Progressed on Prior Fluoropyrimidine Therapy Safety Profile Continues to be Favorable ...
NuCana Appoints Andrew Kay as Board Chairman
December 21, 2020 16:01 ET | NuCana plc
Pharmaceutical Executive Brings a Wealth of Experience to NuCana’s Board of Directors Previously Served as CEO of Algeta, Chairman of Wilson Therapeutics and Chairman of KaNDy Therapeutics ...
Final Data from the Phase Ib Study of Acelarin plus Cisplatin in Patients with Advanced Biliary Tract Cancer Published Online Ahead of Print in The Oncologist
November 30, 2020 16:01 ET | NuCana plc
Acelarin plus Cisplatin’s High Objective Response Rate and Favorable Safety Profile Confirmed NuTide:121 Global Phase III Study Recruitment Ongoing EDINBURGH, United Kingdom, Nov. 30, 2020 (GLOBE...
NuCana Reports Third Quarter 2020 Financial Results and Provides Business Update
November 19, 2020 16:01 ET | NuCana plc
Completed Successful $80 million Public Offering Presented Encouraging Data for NUC-3373 and NUC-7738 at the ESMO Virtual Congress 2020 EDINBURGH, United Kingdom, Nov. 19, 2020 (GLOBE NEWSWIRE) --...
NuCana to Present at the Piper Sandler 32nd Annual Virtual Healthcare Conference
November 17, 2020 16:01 ET | NuCana plc
EDINBURGH, United Kingdom, Nov. 17, 2020 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA) announced today that Hugh Griffith, Chief Executive Officer, and Don Munoz, Chief Financial Officer, will...
NuCana to Present at the Jefferies Virtual London Healthcare Conference
November 12, 2020 16:01 ET | NuCana plc
EDINBURGH, United Kingdom, Nov. 12, 2020 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA) announced today that Hugh Griffith, Chief Executive Officer, and Don Munoz, Chief Financial Officer, will...